Journal article icon

Journal article

Composite grey matter fingerprints for genetic frontotemporal dementia

Abstract:
Background: Brain structural changes in frontotemporal dementia (FTD) can occur decades before symptom onset. Precise characterisation of grey matter changes is necessary for developing models of biomarker progression, while better understanding the trajectory of the pathology is invaluable for prognosis and detecting treatment effects as we enter the era of clinical trials. Methods: Cortical and subcortical grey matter volume and thickness from structural MRI were assessed in a large cohort of 892 participants including presymptomatic and symptomatic carriers of mutations within the three main genetic causes of FTD (C9 open reading-frame 72 (C9orf72), progranulin (GRN) and microtubule-associated protein tau (MAPT)) compared with mutation-negative relatives (controls). We compared the distribution of grey matter changes of each metric at different stages of the disease cross sectionally. We aimed to identify grey matter composites for each genetic group which would show the earliest changes and which separated presymptomatic carriers from controls. Results: While C9orf72 mutation carriers showed widespread presymptomatic grey matter changes, MAPT and particularly GRN mutation carriers showed changes more proximally to symptom onset. Our composite grey matter signatures, which discriminate asymptomatic/prodromal carriers from controls with high to very high areas under the curve, involved bilateral thalami volumes, precuneus and postcentral thickness in C9orf72; left caudal middle frontal thickness, frontal pole and pars orbitalis volumes in GRN; right temporal pole volume and left insula thickness in MAPT mutation carriers. Conclusion: We propose the use of cortical thickness and volume measurements combined from multiple regions into a composite region of interest for each FTD genetic group to identify the earliest changes and track disease progression. Our quasi-longitudinal design illustrates that these regions continue to evolve throughout the symptomatic stages. Investigating how our selected composites progress and validating these in longitudinal samples will be invaluable for future clinical trials.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1136/jnnp-2025-337186

Authors

More by this author
Role:
Author
ORCID:
0000-0002-0267-8590


More from this funder
Funder identifier:
http://dx.doi.org/10.13039/501100020398
Grant:
N/A
More from this funder
Funder identifier:
http://dx.doi.org/10.13039/501100021790
Grant:
N/A
More from this funder
Funder identifier:
https://ror.org/01gavpb45
Grant:
MOP- 371851 & PJT-175242
More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MC_UU_00030/14; MR/T033371/1
More from this funder
Funder identifier:
https://ror.org/05ecdew94
Grant:
N/A


Publisher:
BMJ Publishing Group
Journal:
Journal of Neurology, Neurosurgery and Psychiatry More from this journal
Pages:
jnnp-2025-337186
Article number:
jnnp-2025-337186
Publication date:
2026-02-12
Acceptance date:
2025-12-17
DOI:
EISSN:
1468-330X
ISSN:
0022-3050


Language:
English
Keywords:
Pubs id:
2377015
Local pid:
pubs:2377015
Source identifiers:
3792938
Deposit date:
2026-02-24
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP